Firm advances clinical-stage applications in IBS and liver illness utilizing next-gen intestinal microbiota switch expertise.
Microbiome therapeutics firm EnteroBiotix has efficiently concluded a $34m funding spherical to help the development of medical applications concentrating on a number of persistent situations. The gut microbiome has lengthy been implicated in wholesome growing old and longevity, serving to regulate our immune system and scale back irritation, each of that are concerned in lots of age-related situations. This presents potential avenues for microbiome-targeted interventions, and firms like EnteroBiotix are working to harness the facility of the intestine towards a variety of persistent illnesses.
Based mostly in Glasgow, Scotland, the clinical-stage biotech makes a speciality of intestinal microbiota switch (IMT), which describes the switch of wholesome microbiome communities into the intestinal tract of individuals affected by microbiome-mediated illness. The approach isn’t new, however EnteroBiotix is concentrating on limitations in present practices, offering “standardised and compositionally constant” options designed to revive and improve intestine microbial ecology through orally administered capsules containing colourless, odourless powder.
The brand new funding injection will gas the development of EnteroBiotix’s lead product candidate, EBX-102-02, by way of a Part 2 medical trial concentrating on Irritable Bowel Syndrome (IBS). As well as, it would advance the event of the corporate’s pipeline addressing different situations related to intestine microbiome dysbiosis, together with liver cirrhosis and hepatic encephalopathy, a situation describing adjustments within the mind that happen in sufferers with liver illness.
“This important new funding helps allow our imaginative and prescient of remodeling the usual of take care of sufferers affected by critical situations linked to the intestine microbiome,” mentioned Dr James McIlroy, CEO of EnteroBiotix It can assist speed up the event of our progressive product pipeline and propels us in the direction of our purpose of bringing these progressive remedies to market.”
The financing, consisting of recent fairness and the conversion of mortgage notes, was supported by a consortium of each new and present traders, together with Thairm Bio and Kineticos Life Sciences, alongside the Scottish Nationwide Funding Financial institution, Scottish Enterprise and others.
